Advocacy News

CMS Releases Final DEMPOS Rule, Pump Proposal Not Included

December 21, 2021

On December 21, the Centers for Medicare and Medicaid Services (CMS) issued the Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) final rule. Of note to home infusion providers, the agency is not finalizing its interpretation of the “appropriate for use in the home” requirement in the definition of DME as it applies to certain external infusion pumps.  

CMS noted, “Many commenters believed that the proposal to expand classification of external infusion pumps as DME was unclear, needed more development, and raised safety concerns related to decisions regarding what drug therapies could safely be administered in a home/non-facility setting, as well as concerns about cost-sharing and cost-shifting to beneficiaries. After considering the public comments, CMS is not finalizing the proposed expanded classification of external infusion pumps as DME policy.” 

In lengthy comments to CMS, NHIA cautioned against its strategy of attempting to expand home infusion access under the flawed, outdated Medicare Part B benefit, noting that, “the decision about whether to use an infusion pump should always be based on clinical judgment after performing a complete patient and therapy assessment” and not “a primary criterion determining coverage for home infusion.” 

Instead, the association recommended that CMS not mandate that a pump be used in order for a drug to be covered and consider implementing a modern home infusion therapy services benefit that would provide for an alternate coverage path for drugs that do not require either an infusion pump.  

“While we appreciate that CMS is interested in increasing access to more therapies in the home setting, NHIA is pleased that the agency did not finalize the proposed changes to the external infusion pump benefit under Part B,” said NHIA President and CEO Connie Sullivan, BSPharm. “Medicare beneficiaries deserve a safe, modern, and comprehensive home infusion benefit similar to what has been available in the commercial sector for over 40 years.” 

Related Posts

NHIA Releases Comments on California Senate Bill 958

NHIA submitted comments on California SB 958, the Medication and Patient Safety Act of 2022, supporting amendments to the proposed legislation that allow for infused medications to be administered in the enrollee’s home when the physician and patient determine it is in the patient’s best interest and weighing in on various other aspects of the bill.

Read More »

NHIA Submits Comments on DIR Proposed Rule

NHIA submitted comments on a CMS proposed rule: Medicare and Medicaid Programs; CY 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs, which would alter the way pharmacy price concessions, including direct and indirect remuneration (DIR fees), are calculated by pharmacy benefit managers (PBMs).

Read More »